PrestoBlue cell viability assay

IN Ikuko Takeda Nakamura
SK Shinji Kohsaka
MI Masachika Ikegami
HI Hiroshi Ikeuchi
TU Toshihide Ueno
KL Kunhua Li
TB Tyler S. Beyett
TK Takafumi Koyama
TS Toshio Shimizu
NY Noboru Yamamoto
FT Fumiyuki Takahashi
KT Kazuhisa Takahashi
ME Michael J. Eck
HM Hiroyuki Mano
ask Ask a question
Favorite

The transformed 3T3 cells expressing each FGFR mutant were cultivated in 96-well plates in DMEM-F12 medium (100 µL of culture medium per well) with 1.5% FBS and FGFR inhibitor at concentrations ranging from 0.1 nM to 10 µM for 5 days. The transformed Ba/F3 cells expressing each FGFR mutant were cultivated in 96-well plates in RPMI 1640 medium with 20% FBS and FGFR inhibitor at concentrations ranging from 0.1 nM to 10 µM for 5 days. Subsequently, 10 μL of PrestoBlue (Thermo Fisher Scientific) was added to the plates, and the fluorescence was measured after 3 h of incubation (excitation 530 nm, emission 590 nm) at 0.1 s. The fluorescence intensities of wells without cells were used as negative controls, and dose-response curves were fit the observed cell viabilities using the “drc package” in R language58. The three-parameter sigmoidal function LL2.3 was used with the following settings: y0 (response without drug) = 0, robust = “mean”, method = “Nelder-Mead”. The IC50 was defined as the inflection point on a dose-response curve.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A